Daiichi Life Insurance Co. Ltd. Lowers Stake in Pfizer Inc. $PFE

Daiichi Life Insurance Co. Ltd. trimmed its stake in Pfizer Inc. (NYSE:PFE) by 29.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 170,206 shares of the biopharmaceutical company’s stock after selling 72,630 shares during the period. Daiichi Life Insurance Co. Ltd.’s holdings in Pfizer were worth $4,099,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also added to or reduced their stakes in the company. Godfrey Financial Associates Inc. bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $26,000. Keb Asset Management LLC bought a new position in Pfizer in the second quarter worth approximately $26,000. HFM Investment Advisors LLC grew its stake in Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares in the last quarter. Evolution Wealth Management Inc. increased its holdings in Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 566 shares during the period. Finally, Abound Financial LLC purchased a new position in Pfizer during the 4th quarter worth $31,000. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

PFE has been the subject of several research reports. Bank of America lowered their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, July 10th. HSBC lowered Pfizer from a “buy” rating to a “hold” rating and cut their price target for the company from $32.00 to $28.00 in a research note on Monday, July 6th. Citigroup increased their target price on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, April 29th. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Finally, UBS Group reiterated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research note on Wednesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $28.28.

Pfizer Trading Down 0.4%

PFE opened at $27.97 on Tuesday. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The firm has a market cap of $159.41 billion, a price-to-earnings ratio of 36.80 and a beta of 0.34. Pfizer Inc. has a 12 month low of $23.58 and a 12 month high of $28.75. The stock has a fifty day moving average price of $25.34 and a 200-day moving average price of $26.26.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter last year, the company earned $0.78 earnings per share. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.1%. Pfizer’s payout ratio is presently 226.32%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.